# Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]

> **NCT06511193** · — · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 152 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Budenoside/Glycopyrronium/Formoterol

## Key facts

- **NCT ID:** NCT06511193
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-17
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06511193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06511193, "Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06511193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*